These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 24027111)

  • 21. Statistical Primer on Biosimilar Clinical Development.
    Isakov L; Jin B; Jacobs IA
    Am J Ther; 2016; 23(6):e1903-e1910. PubMed ID: 26766293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physicochemical and biological characterization of a biosimilar trastuzumab.
    López-Morales CA; Miranda-Hernández MP; Juárez-Bayardo LC; Ramírez-Ibáñez ND; Romero-Díaz AJ; Piña-Lara N; Campos-García VR; Pérez NO; Flores-Ortiz LF; Medina-Rivero E
    Biomed Res Int; 2015; 2015():427235. PubMed ID: 26075238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Diversity of Biosimilar Design and Development: Implications for Policies and Stakeholders.
    Grampp G; Ramanan S
    BioDrugs; 2015 Dec; 29(6):365-72. PubMed ID: 26581551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J; Kudrin A
    Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach.
    Candelaria M; Gonzalez D; Fernández Gómez FJ; Paravisini A; Del Campo García A; Pérez L; Miguel-Lillo B; Millán S
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):515-527. PubMed ID: 29362903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A consistency approach for evaluation of biosimilar products.
    Tsou HH; Chang WJ; Hwang WS; Lai YH
    J Biopharm Stat; 2013; 23(5):1054-66. PubMed ID: 23957515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Demonstrating biosimilar and originator antidrug antibody binding comparability in antidrug antibody assays: a practical approach.
    Ryding J; Stahl M; Ullmann M
    Bioanalysis; 2017 Sep; 9(18):1395-1406. PubMed ID: 28920451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sample size calculations for the development of biosimilar products.
    Kang SH; Kim Y
    J Biopharm Stat; 2014; 24(6):1215-24. PubMed ID: 25032735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Key considerations in the preclinical development of biosimilars.
    Bui LA; Hurst S; Finch GL; Ingram B; Jacobs IA; Kirchhoff CF; Ng CK; Ryan AM
    Drug Discov Today; 2015 May; 20 Suppl 1():3-15. PubMed ID: 25912284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Switching on Pharmacokinetics of Therapeutic Biologics and Interchangeability Assessment-A Simulation Study.
    Ji P; Ren Y; Li L; Schrieber SJ; Pisal D; Hallett W; Wang Y; Sahajwalla CG
    J Clin Pharmacol; 2022 Jan; 62(1):36-45. PubMed ID: 34411322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs.
    Civoli F; Kasinath A; Cai XY; Wadhwa M; Exley A; Oldfield P; Alvandkouhi S; Schaffar G; Chappell J; Bowsher R; Devanarayan V; Marini J; Rebarchak S; Anderson M; Koppenburg V; Lester T
    AAPS J; 2019 Dec; 22(1):7. PubMed ID: 31792633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation.
    Scott BJ; Klein AV; Wang J
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S123-32. PubMed ID: 24965228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biosimilars entering the clinic without animal studies. A paradigm shift in the European Union.
    van Aerts LA; De Smet K; Reichmann G; van der Laan JW; Schneider CK
    MAbs; 2014; 6(5):1155-62. PubMed ID: 25517301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Innovative Design and Analysis for PK/PD Biosimilar Bridging Studies with Multiple References.
    Song F; Zheng X; Wang Y; Chow SC; Sun H
    AAPS J; 2021 Nov; 24(1):3. PubMed ID: 34850298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing biosimilarity and interchangeability of biosimilar products.
    Chow SC
    Stat Med; 2013 Feb; 32(3):361-3. PubMed ID: 23307569
    [No Abstract]   [Full Text] [Related]  

  • 36. Recommendations for the Development and Validation of Neutralizing Antibody Assays in Support of Biosimilar Assessment.
    Gouty D; Cai CC; Cai XY; Kasinath A; Kumar V; Alvandkouhi S; Yang J; Pederson S; Babbitt B; Peritt D; Rudy A; Koppenburg V; Dasilva A; Ullmann M; Liu S; Satterwhite C
    AAPS J; 2017 Dec; 20(1):25. PubMed ID: 29285735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The challenge of indication extrapolation for infliximab biosimilars.
    Feagan BG; Choquette D; Ghosh S; Gladman DD; Ho V; Meibohm B; Zou G; Xu Z; Shankar G; Sealey DC; Russell AS
    Biologicals; 2014 Jul; 42(4):177-83. PubMed ID: 24962198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analytical and bioanalytical assay challenges to support comparability studies for biosimilar drug development.
    Cai XY; Wake A; Gouty D
    Bioanalysis; 2013 Mar; 5(5):517-20. PubMed ID: 23425265
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparative immunogenicity assessment: a critical consideration for biosimilar development.
    Liu PM; Zou L; Sadhu C; Shen WD; Nock S
    Bioanalysis; 2015; 7(3):373-81. PubMed ID: 25697194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency estimator for assessing of follow-on biologics.
    Lu Y; Zhang ZZ; Chow SC
    J Biopharm Stat; 2014; 24(6):1280-97. PubMed ID: 25072640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.